Sodium-glucose co-transporter type 2 (SGLT-2) inhibitors hold promise in improving quality of life by addressing hypervolemia, obesity, and lipid irregularities. This evidence concerns the gene SLC5A2 and obesity due to melanocortin 4 receptor deficiency.